We partner with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure and enables us to implement a broader and more effective development strategy
In addition, in line with our strategy we have initiated out-licensing discussions with multiple large biopharmaceutical companies. These licencing discussions are focused on partnerships for:
- the Company’s core cancer therapeutic programs: Midkine antibodies, Midkine RNA therapeutics, STAT-6 siRNA therapeutics and MK cell therapy; and
- non-core applications such as diagnostics, biomarker detection and therapy areas outside of cancer.
If you are interested in partnering Roquefort Therapeutics please contact us on info@roquefortplc.com
